PURPOSE: Ten years after the first clinical studies, the clinical impact of myeloid growth factors in acute myeloid leukemia is still unclear. One of the objectives of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques (GOELAM) 2 trial was to evaluate the benefit of granulocyte colony-stimulating factor (GCSF) given only after the two courses of intensive consolidation chemotherapy (ICC) used to maintain complete remission (CR). PATIENTS AND METHODS: One hundred ninety-four patients who were in CR after induction treatment were randomly assigned to receive G-CSF (100 patients) or no G-CSF (94 patients) after two courses of ICC (ICC 1, high-dose cytarabine plus mitoxantrone; ICC 2, amsacrine plus etoposide). G-CSF (filgrastim) was administered from the day after chemotherapy until granulocyte recovery at a daily dose of 5 microg/kg. RESULTS: In the G-CSF group, the median duration of neutropenia (< 0.5 x 10(9)/L) was dramatically reduced, both after ICC 1 (12 v 19 days, P <.001) and after ICC 2 (20 v 28 days, P <.001). The median duration of hospitalization was also significantly shorter in the G-CSF group (24 v 27 days after ICC 1, P <.001; 29 v 34 days after ICC 2, P <. 001). The median duration of intravenous antibiotics was significantly reduced after ICC 1 and ICC 2, and the median duration of antifungal therapy was significantly reduced after ICC 1. However, the incidence of microbiologically documented infections, the toxic death rate, the 2-year disease-free survival, and the 2-year overall survival were not affected by G-CSF administration. Moreover, the median interval between ICC1 and ICC2 was reduced by only 2 days, and the number of patients undergoing ICC2 was not increased in the G-CSF arm. CONCLUSION:G-CSF should be administered routinely after ICC to reduce the duration of neutropenia and hospitalization. However, G-CSF did not seem to significantly increase the feasibility of this two-course program or modify overall outcome.
RCT Entities:
PURPOSE: Ten years after the first clinical studies, the clinical impact of myeloid growth factors in acute myeloid leukemia is still unclear. One of the objectives of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques (GOELAM) 2 trial was to evaluate the benefit of granulocyte colony-stimulating factor (GCSF) given only after the two courses of intensive consolidation chemotherapy (ICC) used to maintain complete remission (CR). PATIENTS AND METHODS: One hundred ninety-four patients who were in CR after induction treatment were randomly assigned to receive G-CSF (100 patients) or no G-CSF (94 patients) after two courses of ICC (ICC 1, high-dose cytarabine plus mitoxantrone; ICC 2, amsacrine plus etoposide). G-CSF (filgrastim) was administered from the day after chemotherapy until granulocyte recovery at a daily dose of 5 microg/kg. RESULTS: In the G-CSF group, the median duration of neutropenia (< 0.5 x 10(9)/L) was dramatically reduced, both after ICC 1 (12 v 19 days, P <.001) and after ICC 2 (20 v 28 days, P <.001). The median duration of hospitalization was also significantly shorter in the G-CSF group (24 v 27 days after ICC 1, P <.001; 29 v 34 days after ICC 2, P <. 001). The median duration of intravenous antibiotics was significantly reduced after ICC 1 and ICC 2, and the median duration of antifungal therapy was significantly reduced after ICC 1. However, the incidence of microbiologically documented infections, the toxic death rate, the 2-year disease-free survival, and the 2-year overall survival were not affected by G-CSF administration. Moreover, the median interval between ICC1 and ICC2 was reduced by only 2 days, and the number of patients undergoing ICC2 was not increased in the G-CSF arm. CONCLUSION:G-CSF should be administered routinely after ICC to reduce the duration of neutropenia and hospitalization. However, G-CSF did not seem to significantly increase the feasibility of this two-course program or modify overall outcome.
Authors: Grace Kam; Richard Yiu; Yvonne Loh; Ai Leen Ang; Ling Ling Yueh; Yeow Tee Goh; Gee Chuan Wong Journal: Support Care Cancer Date: 2014-08-27 Impact factor: 3.603
Authors: Wolfgang R Sperr; Susanne Herndlhofer; Karoline Gleixner; Michael Girschikofsky; Ansgar Weltermann; Sigrid Machherndl-Spandl; Thamer Sliwa; Rainer Poehnl; Veronika Buxhofer-Ausch; Karin Strecker; Gregor Hoermann; Paul Knoebl; Ulrich Jaeger; Klaus Geissler; Michael Kundi; Peter Valent Journal: Am J Hematol Date: 2017-08-17 Impact factor: 10.047
Authors: Hiroto Inaba; Xueyuan Cao; Stanley Pounds; Ching-Hon Pui; Jeffrey E Rubnitz; Raul C Ribeiro; Bassem I Razzouk Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Jorge Sierra; Jeffrey Szer; Jeannine Kassis; Richard Herrmann; Mario Lazzarino; Xavier Thomas; Stephen J Noga; Nigel Baker; Roger Dansey; Alberto Bosi Journal: BMC Cancer Date: 2008-07-10 Impact factor: 4.430
Authors: Ana Ls Vanz; Gaby Renard; Mario S Palma; Jocelei M Chies; Sérgio L Dalmora; Luiz A Basso; Diógenes S Santos Journal: Microb Cell Fact Date: 2008-04-04 Impact factor: 5.328